deltatrials
Completed PHASE1/PHASE2 NCT00050648

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis.

Sponsor: Facet Biotech

Conditions Psoriasis
Interventions Cyclosporine Daclizumab cyclosporine and Daclizumab
Updated 6 times since 2017 Last updated: Mar 12, 2009 Started: Oct 31, 1997 Primary completion: Sep 30, 2004 Completion: Apr 30, 2008

Listed as NCT00050648, this PHASE1/PHASE2 trial focuses on Psoriasis and remains completed. Sponsored by Facet Biotech, it has been updated 6 times since 1997, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1_PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1_PHASE2

    First recorded

Oct 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Facet Biotech
  • Rockefeller University
Data source: Rockefeller University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States